Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
GP IIb/IIIa Inhibitor During Medical Management and After PCI: CAPTURE, PURSUIT, PRISM- PLUS Medical Rx Post PCI Death or MI 10% 8% 6% 4% 2% N=12,296 P=.001 Control GP IIb/IIIa inhibitor 4.3% 2.9% N=2754 P=.001 8.0% 4.9% 0% 0 Boersma E, et al. Circulation. 1999;100:2045-2048 +24 h +48 h +72 h +24 h +48 h PCI
IIb/IIIa: Strategia upstream o downstream
- Page 1 and 2: P come piastrine, come prezzemolo
- Page 3 and 4: Formazione del trombo nelle ACS sen
- Page 5 and 6: GP IIb-IIIa Inhibitors costituiscon
- Page 8 and 9: Cardiologia “De Gasperis”- Nigu
- Page 10 and 11: Inibitori GPIIb/IIIa Artist’s con
- Page 12: Characteristics of GP IIb/IIIa Inhi
- Page 15 and 16: Patogenesi delle Sindromi Coronaric
- Page 17 and 18: Sindromi Coronariche Acute ST-segme
- Page 19: 8 16 Lancet 1997; 349:1429-35 35
- Page 22 and 23: UA/NSTEMI Beneficio solo se PCI
- Page 24 and 25: % of Patients IIb/IIIa Inhibition w
- Page 28 and 29: Peterson E.D.et al.: Early use of g
- Page 30 and 31: ISAR-COOL study - Pre-procedural ou
- Page 32 and 33: CAPTURE Results by Troponin T Statu
- Page 34 and 35: GP IIb/IIIa Inhibition in Diabetics
- Page 36 and 37: Gli inibitori GP IIb/IIIa IIIa ridu
- Page 38 and 39: ESC PCI guidelines 2004 2004 Recomm
- Page 40 and 41: SCA: UA/NSTEMI L’applicazione del
- Page 42 and 43: Coronarografia in base a età e TIM
- Page 44 and 45: Sindromi Coronariche Acute ST-segme
- Page 46 and 47: Occlusive thrombus contains Fibrin
- Page 48 and 49: Abciximab Improves ST Res-90 min ST
- Page 50 and 51: RAPPORT, ISAR 2, ADMIRAL, CADILLAC
- Page 52 and 53: 5 GPIIb/IIIa inhibitors trials in P
- Page 54 and 55: BMS and abciximab display a synergi
- Page 56 and 57: Study design Inclusion Criteria: ST
- Page 58 and 59: Multi-STRATEGY MULTIcenter evaluati
- Page 60 and 61: GUSTO V AMI GUSTO V - Trial Schemat
- Page 62 and 63: IIb/IIIa Varie...ed eventuali
- Page 64 and 65: IIb/IIIa e PCI: Nei pazienti stabil
- Page 66: Conclusioni Glycoprotein IIb/IIIa I
GP <strong>IIb</strong>/<strong>IIIa</strong> Inhib<strong>it</strong>or During Medical Management<br />
and After PCI: CAPTURE, PURSUIT, PRISM-<br />
PLUS<br />
Medical Rx<br />
Post PCI<br />
Death or MI<br />
10%<br />
8%<br />
6%<br />
4%<br />
2%<br />
N=12,296<br />
P=.001<br />
Control<br />
GP <strong>IIb</strong>/<strong>IIIa</strong> inhib<strong>it</strong>or<br />
4.3%<br />
2.9%<br />
N=2754<br />
P=.001<br />
8.0%<br />
4.9%<br />
0%<br />
0<br />
Boersma E, et al. Circulation. 1999;100:2045-2048<br />
+24 h +48 h +72 h +24 h +48 h<br />
PCI
Change language